Evidence map›Paper›PMID 26059745›Full record

Trial reportEuropean journal of clinical nutrition2016

A combination of isolated phytochemicals and botanical extracts lowers diastolic blood pressure in a randomized controlled trial of hypertensive subjects.

S Biesinger, H A Michaels, A S Quadros, Y Qian, A B Rabovsky, R S Badger, T Jalili

Registry-linked trialAbstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in European journal of clinical nutrition, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01106170 (A Double-Blind, Placebo-Controlled, Crossover Evaluation of a Grape Seed Extract and Quercetin Supplement), which is not on this map. Cited by 32 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 5 pooled it
4.0field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01106170 phase1completednot on this map

A Double-Blind, Placebo-Controlled, Crossover Evaluation of a Grape Seed Extract and Quercetin Supplement (Provex CV) to Reduce Markers of Inflammatory Cytokines and Blood Pressure in Subjects With Metabolic Syndrome

TypeinterventionalSponsorUniversity of UtahRan2010 to 2011Enrolled20ConditionsBlood PressureArmsProvex CV, placebo
3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 5 syntheses or guidelines pooled it, 79 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. The efficacy and safety ofDrug design, development and therapy · 2018
    Trial
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Potential Therapeutic Properties of the Leaf ofPlants (Basel, Switzerland) · 2022
    Article
  18. Review
  19. Review
  20. SIRT1: A Novel Protective Molecule in Pre-eclampsia.International journal of medical sciences · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

S BiesingerDivision of Nutrition, University of Utah, Salt Lake City, UT, USA.
H A MichaelsDivision of Nutrition, University of Utah, Salt Lake City, UT, USA.
A S QuadrosDivision of Nutrition, University of Utah, Salt Lake City, UT, USA.
Y QianDivision of Nutrition, University of Utah, Salt Lake City, UT, USA.
A B RabovskyResearch and Technology Development, Melaleuca Inc., Idaho Falls, ID, USA.
R S BadgerDivision of Cardiology, University of Utah, Salt Lake City, UT, USA.
T JaliliDivision of Nutrition, University of Utah, Salt Lake City, UT, USA.
University of Utah · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

objectivesIsolated phytochemicals have been shown to reduce blood pressure; however, combinations of phytochemicals have rarely been tested in humans. We hypothesized that a combination of extracts from grape seed and skin (330 mg), green tea (100 mg), resveratrol (60 mg) and a blend of quercetin, ginkgo biloba and bilberry (60 mg) would reduce blood pressure (BP) in hypertensive subjects. SUBJECTS/

methodsEighteen individuals meeting BP requirements (⩾130 mm Hg systolic or ⩾85 mm Hg diastolic) and criteria for metabolic syndrome were enrolled in a double-blinded, placebo-controlled, crossover trial (ClinicalTrials.gov, NCT01106170). The 28-day placebo and supplement arms were separated by a 2-week washout period, and 14 -h daytime ambulatory BP was assessed at baseline and at the end point of each arm.

resultsBP was not altered after placebo. After supplement treatment, diastolic pressure was reduced by 4.4 mm Hg (P=0.024, 95% CI, 0.6-8.1), systolic pressure was unchanged and mean arterial pressure trended (P=0.052) toward reduction. Serum angiotensin-converting enzyme activity was similar between placebo and supplement arms, but urinary nitrate and nitrite concentrations were significantly increased (P=0.022) after supplementation. Human aortic endothelial cells treated with metabolites of the polyphenols used in the human supplement trial had a significant increase (P=0.005) in insulin-stimulated eNOS phosphorylation and greater (P<0.001) accumulation of nitrates/nitrites.

conclusionsOur clinical and in vitro data support the theory that this combination of polyphenols reduced diastolic pressure by potentiating eNOS activation and nitric oxide production. Such supplements may have clinical relevance as stand-alone or adjunct therapy to help reduce BP.

Indexed as

Dietary SupplementsPhytotherapyAdultAntihypertensive AgentsAntioxidantsBlood PressureCross-Over StudiesDouble-Blind MethodEndothelium, VascularFemaleHumansHypertensionMagnoliopsidaMaleMetabolic SyndromeMiddle AgedAntihypertensive AgentsAntioxidantsNitric OxideNitric Oxide Synthase Type IIINOS3 protein, humanPhytochemicalsPlant ExtractsPolyphenolsQuercetinResveratrolStilbenes

Identifiers

PMID26059745
OpenAlexW914116849

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.